Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Eli Lilly has just executed on a turnkey antibody platform deal with Tillman Gerngross’s Adimab.
We don’t know the deal terms, but Lilly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
